GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » Cyclically Adjusted Price-to-FCF

GSK (GSK) Cyclically Adjusted Price-to-FCF : 11.75 (As of Apr. 27, 2024)


View and export this data going back to 1987. Start your Free Trial

What is GSK Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), GSK's current share price is $41.11. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.50. GSK's Cyclically Adjusted Price-to-FCF for today is 11.75.

The historical rank and industry rank for GSK's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

GSK' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.39   Med: 13.05   Max: 19.16
Current: 12.04

During the past years, GSK's highest Cyclically Adjusted Price-to-FCF was 19.16. The lowest was 9.39. And the median was 13.05.

GSK's Cyclically Adjusted Price-to-FCF is ranked better than
84.62% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.81 vs GSK: 12.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.483. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.50 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GSK's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Price-to-FCF Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.02 11.16 12.90 10.25 10.56

GSK Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.25 10.38 10.09 10.88 10.56

Competitive Comparison of GSK's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.



GSK Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GSK's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=41.11/3.5
=11.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.483/130.0000*130.0000
=1.483

Current CPI (Dec. 2023) = 130.0000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.493 99.300 0.645
201406 0.323 99.800 0.421
201409 0.712 100.000 0.926
201412 1.321 99.900 1.719
201503 0.004 99.600 0.005
201506 -0.158 100.100 -0.205
201509 0.030 100.200 0.039
201512 0.624 100.400 0.808
201603 -0.084 100.400 -0.109
201606 0.555 101.000 0.714
201609 0.852 101.500 1.091
201612 1.404 102.200 1.786
201703 0.457 102.700 0.578
201706 0.259 103.500 0.325
201709 0.946 104.300 1.179
201712 1.477 105.000 1.829
201803 0.359 105.100 0.444
201806 0.661 105.900 0.811
201809 1.082 106.600 1.320
201812 2.211 107.100 2.684
201903 0.238 107.000 0.289
201906 0.479 107.900 0.577
201909 1.270 108.400 1.523
201912 1.740 108.500 2.085
202003 0.384 108.600 0.460
202006 1.469 108.800 1.755
202009 0.137 109.200 0.163
202012 2.199 109.400 2.613
202103 -0.016 109.700 -0.019
202106 0.513 111.400 0.599
202109 0.924 112.400 1.069
202112 2.109 114.700 2.390
202203 1.278 116.500 1.426
202206 0.571 120.500 0.616
202209 0.466 122.300 0.495
202212 0.687 125.300 0.713
202303 -0.283 126.800 -0.290
202306 0.381 129.400 0.383
202309 1.032 130.100 1.031
202312 1.483 130.000 1.483

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (NYSE:GSK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GSK Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK (GSK) Headlines

From GuruFocus

Top 5 3rd Quarter Trades of Parallax Volatility Advisers, L.P.

By GuruFocus Research GuruFocus Editor 11-22-2022

GSK: Step-Changing for Growth

By Pavaki Capital 11-16-2022

Haleon Proves Its Mettle After GSK Spinoff

By Margaret Moran 12-06-2022

Campbell & CO Investment Adviser LLC Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023

Signature Wealth Management Group Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-10-2023

Kahn Brothers Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 4th Quarter Trades of HealthInvest Partners AB

By GuruFocus Research GuruFocus Editor 02-18-2023